Literature DB >> 22544188

HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries.

Diane E Bennett1, Michael R Jordan, Silvia Bertagnolio, Steven Y Hong, Giovanni Ravasi, James H McMahon, Ahmed Saadani, Karen F Kelley.   

Abstract

The World Health Organization developed a set of human immunodeficiency virus drug resistance (HIVDR) early warning indicators (EWIs) to assess antiretroviral therapy clinic and program factors associated with HIVDR. EWIs are monitored by abstracting data routinely recorded in clinical records, and the results enable clinics and program managers to identify problems that should be addressed to minimize preventable emergence of HIVDR in clinic populations. As of June 2011, 50 countries monitored EWIs, covering 131 686 patients initiating antiretroviral treatment between 2004 and 2009 at 2107 clinics. HIVDR prevention is associated with patient care (appropriate prescribing and patient monitoring), patient behavior (adherence), and clinic/program management efforts to reduce treatment interruptions (follow up, retention on first-line ART, procurement and supply management of antiretroviral drugs). EWIs measure these factors and the results have been used to optimize patient and population treatment outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544188      PMCID: PMC3338314          DOI: 10.1093/cid/cis207

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  42 in total

1.  The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda.

Authors:  J T Crane; A Kawuma; J H Oyugi; J T Byakika; A Moss; P Bourgois; D R Bangsberg
Journal:  AIDS Behav       Date:  2006-07

2.  Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring.

Authors:  James H McMahon; Michael R Jordan; Karen Kelley; Silvia Bertagnolio; Steven Y Hong; Christine A Wanke; Sharon R Lewin; Julian H Elliott
Journal:  Clin Infect Dis       Date:  2011-01-18       Impact factor: 9.079

3.  The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.

Authors:  Charles F Gilks; Siobhan Crowley; René Ekpini; Sandy Gove; Jos Perriens; Yves Souteyrand; Don Sutherland; Marco Vitoria; Teguest Guerma; Kevin De Cock
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

4.  Impact of adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil.

Authors:  L F Brigido; R Rodrigues; J Casseb; D Oliveira; M Rossetti; P Menezes; A J Duarte
Journal:  AIDS Patient Care STDS       Date:  2001-11       Impact factor: 5.078

5.  Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults. A qualitative study.

Authors:  Jean B Nachega; Amy R Knowlton; Andrea Deluca; Jan H Schoeman; Linda Watkinson; Anne Efron; Richard E Chaisson; Gary Maartens
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

6.  Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire.

Authors:  Patricia Fassinou; Narcisse Elenga; François Rouet; Rockiath Laguide; Kouakou A Kouakoussui; Marguerite Timite; Stephane Blanche; Philippe Msellati
Journal:  AIDS       Date:  2004-09-24       Impact factor: 4.177

7.  Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.

Authors:  Jean-Jacques Parienti; Véronique Massari; Diane Descamps; Astrid Vabret; Elisabeth Bouvet; Bernard Larouzé; Renaud Verdon
Journal:  Clin Infect Dis       Date:  2004-04-14       Impact factor: 9.079

8.  Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

Authors:  Richard H Haubrich; Sharon A Riddler; A Gregory DiRienzo; Lauren Komarow; William G Powderly; Karin Klingman; Kevin W Garren; David L Butcher; James F Rooney; David W Haas; John W Mellors; Diane V Havlir
Journal:  AIDS       Date:  2009-06-01       Impact factor: 4.177

Review 9.  Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary.

Authors:  Richard A Murphy; Henry Sunpath; Daniel R Kuritzkes; Francois Venter; Rajesh T Gandhi
Journal:  J Infect Dis       Date:  2007-12-01       Impact factor: 5.226

10.  Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels.

Authors:  Jean-Jacques Parienti; Moupali Das-Douglas; Véronique Massari; David Guzman; Steven G Deeks; Renaud Verdon; David R Bangsberg
Journal:  PLoS One       Date:  2008-07-30       Impact factor: 3.240

View more
  33 in total

1.  Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011.

Authors:  M R Jordan; D E Bennett; M A Wainberg; D Havlir; S Hammer; C Yang; L Morris; M Peeters; A M Wensing; N Parkin; J B Nachega; A Phillips; A De Luca; E Geng; A Calmy; E Raizes; P Sandstrom; C P Archibald; J Perriëns; C M McClure; S Y Hong; J H McMahon; N Dedes; D Sutherland; S Bertagnolio
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

2.  Sharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillance.

Authors:  C F Rowley; I J MacLeod; D Maruapula; B Lekoko; S Gaseitsiwe; M Mine; M Essex
Journal:  J Antimicrob Chemother       Date:  2016-02-29       Impact factor: 5.790

3.  Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa.

Authors:  Eugène Messou; Marie-Laure Chaix; Delphine Gabillard; Vincent Yapo; Thomas-d'Aquin Toni; Albert Minga; Martial Guillaume Kouakou; Eric Ouattara; Christine Rouzioux; Christine Danel; Serge P Eholie; Xavier Anglaret
Journal:  J Acquir Immune Defic Syndr       Date:  2013-10-01       Impact factor: 3.731

4.  Scaling-up health information systems to improve HIV treatment: An assessment of initial patient monitoring systems in Mozambique.

Authors:  Mindy Hochgesang; Sophia Zamudio-Haas; Lissa Moran; Leopoldo Nhampossa; Laura Packel; Hannah Leslie; Janise Richards; Starley B Shade
Journal:  Int J Med Inform       Date:  2016-11-10       Impact factor: 4.046

5.  Early warning indicators for first-line virologic failure independent of adherence measures in a South African urban clinic.

Authors:  Vincent C Marconi; Baohua Wu; Jane Hampton; Claudia E Ordóñez; Brent A Johnson; Dinesh Singh; Sally John; Michelle Gordon; Anna Hare; Richard Murphy; Jean Nachega; Daniel R Kuritzkes; Carlos del Rio; Henry Sunpath
Journal:  AIDS Patient Care STDS       Date:  2013-12       Impact factor: 5.078

Review 6.  Diagnosis of Human Immunodeficiency Virus Infection.

Authors:  Bharat S Parekh; Chin-Yih Ou; Peter N Fonjungo; Mireille B Kalou; Erin Rottinghaus; Adrian Puren; Heather Alexander; Mackenzie Hurlston Cox; John N Nkengasong
Journal:  Clin Microbiol Rev       Date:  2018-11-28       Impact factor: 26.132

7.  Gender-specific risk factors for virologic failure in KwaZulu-Natal: automobile ownership and financial insecurity.

Authors:  Anna Q Hare; Claudia E Ordóñez; Brent A Johnson; Carlos Del Rio; Rachel A Kearns; Baohua Wu; Jane Hampton; Peng Wu; Henry Sunpath; Vincent C Marconi
Journal:  AIDS Behav       Date:  2014-11

8.  Results from implementing updated 2012 World Health Organization Guidance on early-warning indicators of HIV drug resistance in Zimbabwe.

Authors:  More Mungati; Mutsa Mhangara; Janet Dzangare; Owen Mugurungi; Tsitsi Apollo; Elizabeth Gonese; Peter H Kilmarx; Christine C Chakanyuka-Musanhu; Gerald Shambira; Mufuta Tshimanga
Journal:  J Epidemiol Res       Date:  2016

Review 9.  Development of antiretroviral resistance in children with HIV in low- and middle-income countries.

Authors:  Felicity Fitzgerald; Martina Penazzato; Diana Gibb
Journal:  J Infect Dis       Date:  2013-06-15       Impact factor: 5.226

10.  HIV drug resistance early warning indicators in Namibia for public health action.

Authors:  Anna Jonas; Justice Gweshe; Milner Siboleka; Michael Deklerk; Michael Gawanab; Alfons Badi; Victor Sumbi; Dawn Pereko; Abraham Blom; Samson Mwinga; Michael R Jordan; Logan Jerger; Kiger Lau; Steven Y Hong
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.